CA1265050A - Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices - Google Patents
Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matricesInfo
- Publication number
- CA1265050A CA1265050A CA000513596A CA513596A CA1265050A CA 1265050 A CA1265050 A CA 1265050A CA 000513596 A CA000513596 A CA 000513596A CA 513596 A CA513596 A CA 513596A CA 1265050 A CA1265050 A CA 1265050A
- Authority
- CA
- Canada
- Prior art keywords
- sulfated
- blood
- polymer
- sulfatable
- gel matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003114 blood coagulation factor Substances 0.000 title claims abstract description 23
- 108010017384 Blood Proteins Proteins 0.000 title claims abstract description 12
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 10
- 102000004506 Blood Proteins Human genes 0.000 title abstract description 8
- 238000000746 purification Methods 0.000 title abstract description 4
- 239000011159 matrix material Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 18
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 229920000642 polymer Polymers 0.000 claims description 13
- 238000001042 affinity chromatography Methods 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 9
- 210000002381 plasma Anatomy 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 101800004937 Protein C Proteins 0.000 claims description 7
- 102000017975 Protein C Human genes 0.000 claims description 7
- 101800001700 Saposin-D Proteins 0.000 claims description 7
- 150000001252 acrylic acid derivatives Polymers 0.000 claims description 7
- 229960000856 protein c Drugs 0.000 claims description 7
- 102100027378 Prothrombin Human genes 0.000 claims description 5
- 229940019700 blood coagulation factors Drugs 0.000 claims description 5
- 238000007334 copolymerization reaction Methods 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 229940039716 prothrombin Drugs 0.000 claims description 5
- 230000001180 sulfating effect Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000012531 culture fluid Substances 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 3
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- MVBJSQCJPSRKSW-UHFFFAOYSA-N n-[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]prop-2-enamide Chemical compound OCC(CO)(CO)NC(=O)C=C MVBJSQCJPSRKSW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001447 polyvinyl benzene Polymers 0.000 claims description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 108010066124 Protein S Proteins 0.000 claims description 2
- 229940096437 Protein S Drugs 0.000 claims description 2
- 102000029301 Protein S Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims 2
- 101001038021 Lonomia obliqua Lopap Proteins 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000001524 infective effect Effects 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 13
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 235000014633 carbohydrates Nutrition 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 42
- 239000000499 gel Substances 0.000 description 28
- 239000011780 sodium chloride Substances 0.000 description 21
- 239000001509 sodium citrate Substances 0.000 description 11
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 11
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 10
- 108010076282 Factor IX Proteins 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229960004222 factor ix Drugs 0.000 description 10
- 102100022641 Coagulation factor IX Human genes 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 108010094028 Prothrombin Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005670 sulfation reaction Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 230000019635 sulfation Effects 0.000 description 6
- 108010014173 Factor X Proteins 0.000 description 5
- 229930003448 Vitamin K Natural products 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019168 vitamin K Nutrition 0.000 description 5
- 239000011712 vitamin K Substances 0.000 description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 description 5
- 229940046010 vitamin k Drugs 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229910002019 Aerosil® 380 Inorganic materials 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001453 nonthrombogenic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 108010012557 prothrombin complex concentrates Proteins 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VSYMNDBTCKIDLT-UHFFFAOYSA-N [2-(carbamoyloxymethyl)-2-ethylbutyl] carbamate Chemical compound NC(=O)OCC(CC)(CC)COC(N)=O VSYMNDBTCKIDLT-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- HPNSNYBUADCFDR-UHFFFAOYSA-N chromafenozide Chemical compound CC1=CC(C)=CC(C(=O)N(NC(=O)C=2C(=C3CCCOC3=CC=2)C)C(C)(C)C)=C1 HPNSNYBUADCFDR-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- -1 hydroxy silica Chemical compound 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
- B01J20/103—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate comprising silica
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/264—Synthetic macromolecular compounds derived from different types of monomers, e.g. linear or branched copolymers, block copolymers, graft copolymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
- B01J20/28047—Gels
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/291—Gel sorbents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3071—Washing or leaching
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3078—Thermal treatment, e.g. calcining or pyrolizing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3085—Chemical treatments not covered by groups B01J20/3007 - B01J20/3078
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/3092—Packing of a container, e.g. packing a cartridge or column
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/48—Sorbents characterised by the starting material used for their preparation
- B01J2220/4806—Sorbents characterised by the starting material used for their preparation the starting material being of inorganic character
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/54—Sorbents specially adapted for analytical or investigative chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/58—Use in a single column
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Thermal Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Inventor: ROBERT E. JORDAN
Invention: PURIFICATION OF BLOOD CLOTTING
FACTORS AND OTHER BLOOD PROTEINS
ON NON-CARBOHYDRATE SULFATED
MATRICES
ABSTRACT OF THE DISCLOSURE
There is disclosed a non-carbohydrated sulfated matrix and the use thereof to isolate and purify blood clotting factors and other blood proteins by a procedure involving the adsorption of at least one of such factors and proteins onto the non-carbohydrate sulfated matrix followed by elution of such factors and proteins onto the non-carbo-hydrate sulfated matrix followed by elution of such factors and proteins from the matrix.
Invention: PURIFICATION OF BLOOD CLOTTING
FACTORS AND OTHER BLOOD PROTEINS
ON NON-CARBOHYDRATE SULFATED
MATRICES
ABSTRACT OF THE DISCLOSURE
There is disclosed a non-carbohydrated sulfated matrix and the use thereof to isolate and purify blood clotting factors and other blood proteins by a procedure involving the adsorption of at least one of such factors and proteins onto the non-carbohydrate sulfated matrix followed by elution of such factors and proteins onto the non-carbo-hydrate sulfated matrix followed by elution of such factors and proteins from the matrix.
Description
5~
This invention relates to a non-carbohydrate synthetic gel matrix that is useful in a process to isolate and purify blood clotting factors and other blood proteins using affini-ty chromatographic techiyues.
Many useful blood fractions and pro-teins may be obtained from blood and blood plasma by known techniques.
Andersson et al, U.S. Patents 3,842,061 and 3,920,625, disclose a cross-lin~ed sulfated polysaccharlde gel matrix adsorbing agent and the use thereof to isolate and purify antithrombin and blood coagulation factors, respectively, from animal tissue materials such as blood, blood products or plasma fractions.
Menache-Aronson et al, U.S. Patent 4,447,416, the pro-duction of an intermediate purified non-thrombogenic factor IX concentrate containing factor IX in major therapeutic amounts and containing ~actors II, VII and X in minor, non-thrombogenic amounts.
The sulfated matrices used to date all have been based on the use of carbohydrate as the backbone. Although such carbohydrate matrices has been useful especially in laboratory-scale separations, it has become evident that, for large-scale production work, gels having greater strength and flow capacity and resistance to microbial attack would be desirable.
According to this invention, there is provided a sul-fated, synthetic, non-carbohydrate gel matrix adsorbing agent comprising a sulfatable polymer selected from a synthetic organic affinity chromatography gel matrix prepared by polymerization or copolymerization of at least one polymerizable organic monomer and from silica particles followed by sulfation of the polymer backbone by a sulfating agent. In another aspect of this invention, there is provided a process for isolating and purifying blood coagulating, or clotting, factors ~' ' .
.
and other blood proteins comprising contacting blood, plasma, plasma protein concentrates, or tissue culture fluids containing bloo~ coagulating factors or other blood proteins with -the sulfated synthe-tic affinity chromatography gel matrix a~sorbing agen-t according to this invention.
The sulfated synthetic affinity chromatography gel ma-t-rix adsorbing agent may be any organic polymeric mate-rial that is sulfatable and that is useful in affinity chromatographic separation operations. Examples of suitable synthetic gel matrices include polyhydroxylated acrylates and methoacrylates, silica particles, and polyvinylbenzene wherein the hydroxyl groups or benzene moiety can be sulfated by reaction of the hydroxyl groups or benzene moiety with a suitable sulfating agent such as, for example, sulfonyl chloride, chlorosulfonic acid and the like.
Preferably, the sulfated synthetic gel matrix according to this invention comprises a sulfated synthetic poly-hydroxylated acrylate of methacrylate or a polyhydroxysilica particle.
An especially useful sulfated polyhydroxylated acrylate gel matrix is that derived from copolymerization of the monomer, N-acryloyl-2-amino-2-hydroxymethyl-1,3-propane diol, which is commercially available under the trademark TRISACRYL~(Reactifs IBF, France).
An especially useful sulfated polyhydroxy silica particle material is that derived from sulfation of the polyhydroxy silica material commercially available under the trademark ., ~ .
.
- ---- - . : , :
- : : : ,, . :
,~ , NuGel~ P-NP (Separation Industries, Metachem, New Jersey, U.S.A.).
Any conventional procedure for sulfating an organic 5 hydroxyl group or aromatic (i.e. benzene) nucleus may be used to sulfate the synthetic gel matrix. A convenient sulfation procedure useful to sulfate the TRISACRYL and NuGel matric?s mentioned above is a modification of the method reported by Miletich et al., Analytical Bio-o chemistry, 105, 304 - 310 (1980), involving the use of chlorosulfonic acid in pyridine.
Among the blood clotting factors and other blood proteins which may be isolated and purified according to the process 15 of this invention by using the sulfated, synthetic, non-carbohydrate gel matrix of the invention are factor IX, factor X, factor II, factcr VII, F. VIII, protein C, protein S, prothrombin, tissue plasminogen activator (TPA) and the like.
The blood coagulating, or clotting, factors and other proteins thus obtained, whether from plasma or tissue culture fluids using biotechnology, can be formulaked into pharmaceutical preparations for therapeutic use. The 2s pharmaceutical preparations may be treated by known means to render them free of infectious microorganisms such as bacteria and viruses and the like, including hepatitis B
virus and the AIDS-causing agents (AXV, H~LV-III, and LAV
agents). Such treatments include sterile filtration, heat treatment in the wet or dry state, chemical treatment, ultraviolet irradiation, and treatment with colloidal silica.
The following examples illustrate but a few embodiments of 3~ the present invention and are not to be construed as limiting in scope. All parts and percentages are by weight ,., ~,.. ..
.
.
and all temperatures are in degrees Celsius unless other-wise indicated.
EX~MPLES
A. Preparation of sulfated matrices for adsorp~ion of coagulation proteins.
EXAMPLE 1.
o Pr~paration of Sulfated Trisacryl Trisacryl is a synthetic, non carbohydrate gel matrix prepared by the copolymerization of the monomer N-acryloyl-
This invention relates to a non-carbohydrate synthetic gel matrix that is useful in a process to isolate and purify blood clotting factors and other blood proteins using affini-ty chromatographic techiyues.
Many useful blood fractions and pro-teins may be obtained from blood and blood plasma by known techniques.
Andersson et al, U.S. Patents 3,842,061 and 3,920,625, disclose a cross-lin~ed sulfated polysaccharlde gel matrix adsorbing agent and the use thereof to isolate and purify antithrombin and blood coagulation factors, respectively, from animal tissue materials such as blood, blood products or plasma fractions.
Menache-Aronson et al, U.S. Patent 4,447,416, the pro-duction of an intermediate purified non-thrombogenic factor IX concentrate containing factor IX in major therapeutic amounts and containing ~actors II, VII and X in minor, non-thrombogenic amounts.
The sulfated matrices used to date all have been based on the use of carbohydrate as the backbone. Although such carbohydrate matrices has been useful especially in laboratory-scale separations, it has become evident that, for large-scale production work, gels having greater strength and flow capacity and resistance to microbial attack would be desirable.
According to this invention, there is provided a sul-fated, synthetic, non-carbohydrate gel matrix adsorbing agent comprising a sulfatable polymer selected from a synthetic organic affinity chromatography gel matrix prepared by polymerization or copolymerization of at least one polymerizable organic monomer and from silica particles followed by sulfation of the polymer backbone by a sulfating agent. In another aspect of this invention, there is provided a process for isolating and purifying blood coagulating, or clotting, factors ~' ' .
.
and other blood proteins comprising contacting blood, plasma, plasma protein concentrates, or tissue culture fluids containing bloo~ coagulating factors or other blood proteins with -the sulfated synthe-tic affinity chromatography gel matrix a~sorbing agen-t according to this invention.
The sulfated synthetic affinity chromatography gel ma-t-rix adsorbing agent may be any organic polymeric mate-rial that is sulfatable and that is useful in affinity chromatographic separation operations. Examples of suitable synthetic gel matrices include polyhydroxylated acrylates and methoacrylates, silica particles, and polyvinylbenzene wherein the hydroxyl groups or benzene moiety can be sulfated by reaction of the hydroxyl groups or benzene moiety with a suitable sulfating agent such as, for example, sulfonyl chloride, chlorosulfonic acid and the like.
Preferably, the sulfated synthetic gel matrix according to this invention comprises a sulfated synthetic poly-hydroxylated acrylate of methacrylate or a polyhydroxysilica particle.
An especially useful sulfated polyhydroxylated acrylate gel matrix is that derived from copolymerization of the monomer, N-acryloyl-2-amino-2-hydroxymethyl-1,3-propane diol, which is commercially available under the trademark TRISACRYL~(Reactifs IBF, France).
An especially useful sulfated polyhydroxy silica particle material is that derived from sulfation of the polyhydroxy silica material commercially available under the trademark ., ~ .
.
- ---- - . : , :
- : : : ,, . :
,~ , NuGel~ P-NP (Separation Industries, Metachem, New Jersey, U.S.A.).
Any conventional procedure for sulfating an organic 5 hydroxyl group or aromatic (i.e. benzene) nucleus may be used to sulfate the synthetic gel matrix. A convenient sulfation procedure useful to sulfate the TRISACRYL and NuGel matric?s mentioned above is a modification of the method reported by Miletich et al., Analytical Bio-o chemistry, 105, 304 - 310 (1980), involving the use of chlorosulfonic acid in pyridine.
Among the blood clotting factors and other blood proteins which may be isolated and purified according to the process 15 of this invention by using the sulfated, synthetic, non-carbohydrate gel matrix of the invention are factor IX, factor X, factor II, factcr VII, F. VIII, protein C, protein S, prothrombin, tissue plasminogen activator (TPA) and the like.
The blood coagulating, or clotting, factors and other proteins thus obtained, whether from plasma or tissue culture fluids using biotechnology, can be formulaked into pharmaceutical preparations for therapeutic use. The 2s pharmaceutical preparations may be treated by known means to render them free of infectious microorganisms such as bacteria and viruses and the like, including hepatitis B
virus and the AIDS-causing agents (AXV, H~LV-III, and LAV
agents). Such treatments include sterile filtration, heat treatment in the wet or dry state, chemical treatment, ultraviolet irradiation, and treatment with colloidal silica.
The following examples illustrate but a few embodiments of 3~ the present invention and are not to be construed as limiting in scope. All parts and percentages are by weight ,., ~,.. ..
.
.
and all temperatures are in degrees Celsius unless other-wise indicated.
EX~MPLES
A. Preparation of sulfated matrices for adsorp~ion of coagulation proteins.
EXAMPLE 1.
o Pr~paration of Sulfated Trisacryl Trisacryl is a synthetic, non carbohydrate gel matrix prepared by the copolymerization of the monomer N-acryloyl-
2-amino-2-hydroxymethyl-1,3-propane diol. Trisacryl GF
15 2000 is manufactured by Reactifs IBF (France) and was ohtained as an aqueous suspension.
1200 ml of suspended Trisacryl GF 2000 was dehydrated on a sintered glass funnel by sequential washes of distilled water (5 x 1200 ml), methanol (5 x 1200 ml) and acetone (5 x 1200 ml). The acetone-containing cake was spread on an aluminum foil surface and heated with an incandescent lamp in a fume hood until the powder was thoroughly dried (14 hours). The yield of dry Trisacryl powder from this 2s treatment was 321 ~rams.
The sulfation reaction was carried out by a modification of the method previously described for dextran beads by Miletich et al (Analytical Biochemistry, 105, 304 - 310, 1980). The trisacryl powder was added with stirring to a solution of chlorosulfonic acid in pyridine ob~ained by ~he dropwise addition of 428 mls of acid to 2.14 liters of pyridine in a dry ice/ethanol bath. The solution was heated to 70 degrees C to completely dissolve the pyridinium before addition of the trisacryl powder. Once added the suspension was stirred until the powder had absorbed all of the liquid. The reaction mixture was ~ , ,:
:: , ~ ::
maintained at 70 C for 2 hours and then at 50 C for 16 hours.
The wet trisacryl c~ake was transferred to scintered glass 5 funnels on vacuum flasks attached to a water aspirator.
Remaining pyridine solution was collected and combined with the first wash effluents for disposal. The gel was washed with a total of 50 liters of 2M NaCl adjusted to pH lO.
The gel was then further washed with 50 liters of distilled water at pH lO. The final weight of the washed gel was 1580 grams.
The sulfated trisacryl gel was e~uilibrated before use in 10 volumes of a buffer consisting of 0.05 M sodium citrate pH 6.5 and 0.10 M sodium chloride. The equilibrated gel was then packed in the desired chromatographic column.
EXAMPLE 2.
Sulfation of Polyhydroxv Silica Sulfation of polyhydroxy silica (NuGel P-NP obtained from Separation Industries, Metuchen, NJ) was carried out in a similar fashion to that described for Trisacryl in Example 1 above. A quantity of dry glass beads (10 grams) was added to a solution which had been prepared by the addition of 12.5 ml chlorosulfonic acid to 65 ml of pyridine as described in Example 1. The suspension was heated at 70 C
for 16 hours after which the pyridine solution was removed by filtration and the glass beads rapidly washed with 50 volumes of 2 ~ NaCl solution at p~l 10. The glass beads were then washed with 50 volumes of distilled water.
Sulfation of the material could be readily confirmed by a modi~ication of the colorimetric method described by Smith et al ~P.X. Smith, A. X. Mallia and G. T. Hermanson, Anal.
3s Biochem. lO9, 466 - 473, 1980).
, :, ~ ,. ' ,;
. .
The ability of the sulfated polyhyroxysilica gel to adsorb coagulation factors IX a~d X was tested. To 10 ml aliquots of a solution of redissolved PTC powder (0.6% w/v) in 0~05 M sodium citrate pH 6.5 containiny 0.1 M NaCl was added 2 5 grams of either the sulfated or the non-sulfated polyhydroxy silica gel. The suspension was mixed on a tube rocker for 15 minutes after which the suspension was centrifuged at low speed to pellet the gel. The presence of F. IS and F~ X activities was assayed in the respective o supernatants as well as in ~he starting PTC solution and are listed in Table 1.
Table 1 lS Factor X and IX Activities in PTC Solution Adsorbed with Sulfated and Non-sulfated Polyhydroxysilica F. IX ~/ml F. X U/ml Starting PTC solution 2.6 13.4 20 Supernatant of adsorption with non-sulfated poly~
hydroxy silica 5.1 13.4 Supernatant of adsorption with sulfated polyhydroxy silica 1.3 5.9 As is evident from the data in the Table, the supernatant of the adsorption with the sulfated gel contains considerably less of both F. IX and F. X activity than the staxting PTC solution. Some activation of F. IX is apparent after contact with the non-sulfated material.
Nevertheless, the data confirm that the sulfated poly-hydroxysilica gel possesses the ability data confirm that .the sulfated polyhydroxysilica gel possesses the ability to .35 adsorb coagulation factors in apparent contrast to the non-sulfated form.
: :
B. ~se of Sulfa~ed Trisacryl in preparation of partially purified coagulation factors~
EXAMPLE 1.
5 Use of Sulfated Trisacryl for the Preparation of a Partially Purified Factor IX from PTC
by Gradient Elution (3001 - 34) PTC powder, a dried, vitamin K dependent coagulation factor-containing material which is an in~rmediate s~ep in the commercial process for ~he production of Factor IX
- concentrate, was redissolved at 1~ w/v in 0.05 M sodium citrate containing 0.1 M NaCl, pH 6.5. After dissolution ; of the powder, the solution was adsorbed with powdered, fumed silica (Aerosil 380, a product of DeGussa) at a 1 w/v ratio for 45 minutes at 42 C. The suspension was centrifuged and the insoluble pellet of Aerosil and adsorbed materials was discarded. The supernatant was filtered and cooled to 10 C. The chi].led solution was 20 applied to a column (17 cm x 14 cm) containing sulfated Trisacryl and equilibrated in 0.05 M sodium citrate containing 0.1 M NaCl at pH 6.5. Column flow rates were approximately 10 L/hr. Material not binding to the column and eluting as a breakthrough peak was discarded. The 2S applied sample was followed by a volume of equilibration buffer sufficient to reduce the protein in the eluate ~o an A280 ~0.1. A 40 liter gradient of NaCl from 0.1 M to 0.6 M
was then applied to the column and 1 liter fractions collected and analyzed for their protein content and
15 2000 is manufactured by Reactifs IBF (France) and was ohtained as an aqueous suspension.
1200 ml of suspended Trisacryl GF 2000 was dehydrated on a sintered glass funnel by sequential washes of distilled water (5 x 1200 ml), methanol (5 x 1200 ml) and acetone (5 x 1200 ml). The acetone-containing cake was spread on an aluminum foil surface and heated with an incandescent lamp in a fume hood until the powder was thoroughly dried (14 hours). The yield of dry Trisacryl powder from this 2s treatment was 321 ~rams.
The sulfation reaction was carried out by a modification of the method previously described for dextran beads by Miletich et al (Analytical Biochemistry, 105, 304 - 310, 1980). The trisacryl powder was added with stirring to a solution of chlorosulfonic acid in pyridine ob~ained by ~he dropwise addition of 428 mls of acid to 2.14 liters of pyridine in a dry ice/ethanol bath. The solution was heated to 70 degrees C to completely dissolve the pyridinium before addition of the trisacryl powder. Once added the suspension was stirred until the powder had absorbed all of the liquid. The reaction mixture was ~ , ,:
:: , ~ ::
maintained at 70 C for 2 hours and then at 50 C for 16 hours.
The wet trisacryl c~ake was transferred to scintered glass 5 funnels on vacuum flasks attached to a water aspirator.
Remaining pyridine solution was collected and combined with the first wash effluents for disposal. The gel was washed with a total of 50 liters of 2M NaCl adjusted to pH lO.
The gel was then further washed with 50 liters of distilled water at pH lO. The final weight of the washed gel was 1580 grams.
The sulfated trisacryl gel was e~uilibrated before use in 10 volumes of a buffer consisting of 0.05 M sodium citrate pH 6.5 and 0.10 M sodium chloride. The equilibrated gel was then packed in the desired chromatographic column.
EXAMPLE 2.
Sulfation of Polyhydroxv Silica Sulfation of polyhydroxy silica (NuGel P-NP obtained from Separation Industries, Metuchen, NJ) was carried out in a similar fashion to that described for Trisacryl in Example 1 above. A quantity of dry glass beads (10 grams) was added to a solution which had been prepared by the addition of 12.5 ml chlorosulfonic acid to 65 ml of pyridine as described in Example 1. The suspension was heated at 70 C
for 16 hours after which the pyridine solution was removed by filtration and the glass beads rapidly washed with 50 volumes of 2 ~ NaCl solution at p~l 10. The glass beads were then washed with 50 volumes of distilled water.
Sulfation of the material could be readily confirmed by a modi~ication of the colorimetric method described by Smith et al ~P.X. Smith, A. X. Mallia and G. T. Hermanson, Anal.
3s Biochem. lO9, 466 - 473, 1980).
, :, ~ ,. ' ,;
. .
The ability of the sulfated polyhyroxysilica gel to adsorb coagulation factors IX a~d X was tested. To 10 ml aliquots of a solution of redissolved PTC powder (0.6% w/v) in 0~05 M sodium citrate pH 6.5 containiny 0.1 M NaCl was added 2 5 grams of either the sulfated or the non-sulfated polyhydroxy silica gel. The suspension was mixed on a tube rocker for 15 minutes after which the suspension was centrifuged at low speed to pellet the gel. The presence of F. IS and F~ X activities was assayed in the respective o supernatants as well as in ~he starting PTC solution and are listed in Table 1.
Table 1 lS Factor X and IX Activities in PTC Solution Adsorbed with Sulfated and Non-sulfated Polyhydroxysilica F. IX ~/ml F. X U/ml Starting PTC solution 2.6 13.4 20 Supernatant of adsorption with non-sulfated poly~
hydroxy silica 5.1 13.4 Supernatant of adsorption with sulfated polyhydroxy silica 1.3 5.9 As is evident from the data in the Table, the supernatant of the adsorption with the sulfated gel contains considerably less of both F. IX and F. X activity than the staxting PTC solution. Some activation of F. IX is apparent after contact with the non-sulfated material.
Nevertheless, the data confirm that the sulfated poly-hydroxysilica gel possesses the ability data confirm that .the sulfated polyhydroxysilica gel possesses the ability to .35 adsorb coagulation factors in apparent contrast to the non-sulfated form.
: :
B. ~se of Sulfa~ed Trisacryl in preparation of partially purified coagulation factors~
EXAMPLE 1.
5 Use of Sulfated Trisacryl for the Preparation of a Partially Purified Factor IX from PTC
by Gradient Elution (3001 - 34) PTC powder, a dried, vitamin K dependent coagulation factor-containing material which is an in~rmediate s~ep in the commercial process for ~he production of Factor IX
- concentrate, was redissolved at 1~ w/v in 0.05 M sodium citrate containing 0.1 M NaCl, pH 6.5. After dissolution ; of the powder, the solution was adsorbed with powdered, fumed silica (Aerosil 380, a product of DeGussa) at a 1 w/v ratio for 45 minutes at 42 C. The suspension was centrifuged and the insoluble pellet of Aerosil and adsorbed materials was discarded. The supernatant was filtered and cooled to 10 C. The chi].led solution was 20 applied to a column (17 cm x 14 cm) containing sulfated Trisacryl and equilibrated in 0.05 M sodium citrate containing 0.1 M NaCl at pH 6.5. Column flow rates were approximately 10 L/hr. Material not binding to the column and eluting as a breakthrough peak was discarded. The 2S applied sample was followed by a volume of equilibration buffer sufficient to reduce the protein in the eluate ~o an A280 ~0.1. A 40 liter gradient of NaCl from 0.1 M to 0.6 M
was then applied to the column and 1 liter fractions collected and analyzed for their protein content and
3~ immunologically detectable amounts of coagulation Factors IX and X as well as Protein C.
The elution profile of the column is shown in ~i~ure 1.
Fractions containing immunologically identifiable amounts 3s of Factors IX, X and Protein C are indicated in the Figure.
Protein C and Factor X were poorly resolved and eluted ~ Tî~e~or~
~ . ., .
early in the gradient at a sodium chloride concentration of approximately 0.15 - 0.3 M. Factor IX was observ~d to elute later in the gradient at approximately 0.4 M NaCl although there was some overlap with F. X.
The Factor IX-containing regions of the elution of similar column runs were pooled and dialyzed vs. 0.015 M sodium citrate containing 0.12 M NaCl. After concentration and sterile filtration, a partially purified F. IX preparation was obtained for animal studies with the following characteristics:
Factor IX activity 30.2 units/ml Protein concentration 4.41 mg/ml 15 F. IX spec. activity 6.85 units/mg NAPTT 1:10 163 sec 1:100 312 sec EXAMPLE 2.
Rapid Chromatography of DEAE Eluate on Sulfated Trisacryl with Quantitation of Factors II, VII, IX and X
A concentrate containing vitamin K-dependent clotting factors was obtained by contacting Effluent I plasma with 2s DE~E Sephadex and eluting the adsorbed gel as follows, After removal of the spent Effluent I, the DEAE gel was sequentially washed with ~1) 0.2 M sodium bicarbonate, ~2) 0.3 M sodium bicarbonate, and (3) 0.2 M sodium chloride containing 0.01 M sodium citrate, pH 6.5, The Factor IX
30 and other vitamin K-dependent fa~tors were then eluted from the DEAE gel with a buffex containing O.055 ~ NaCl and 0.01 M sodium citrate, p~l 6.5. The eluate was diafiltered against six volume exchanges of 0,05 M sodium citrate containing 0.1 M NaCl ! pH 6.5. 73 L of eluate were 3s ob ained and aliquots were frozen for ~ubsequent chromato-graphic studies. The content of clotting factors in the ~ T~A~th)~rl~
-~ CL-114 ,, :
~ .
., .
~ 3 g dialyzed eluate expressed as total units is given in Table .
Table 2 sContent of Vitamin K-dependent Clotting Factors in the Dialy~ed Eluate from DEAE Sephadex~
Contact of Eluate I
Units/ml To~al Units 10 Factor II (prothrombin) 12.0 876,000 Factor VII 2.5 182,130 Factor IX - 6.6 481,800 Factor X 12.8 919,800 Protein C positive for antigen lS Protein S- positive for antigen For the purpose of determining maximum flow characteristics of the sulfated trisacryl gel, a column of the following dimensions was constructed: height ~ 5 cml `, 20 diameter = 25 cm. B.7 liters of th DEAE elute described above was treated with Aerosil 380 at 0.25% w/v at 5 C for 60 minutes. The insoluble Aerosil was removed by filtra-tion and the clariied eluate applied to the sulfated trisacryl column at 24 liters/hour. ~Flow rates of up to 2S 60 liters per hour were obtained with this column configuration without visible deformation of gel or marked loss of column performance~. The elution profile of the column is shown in Figure 2. After application of the clarified DEAE elute, the column was washed with 0.1 M
NaCl, 0.05 M sodium citrate, pH 6~5. Separate step elutions were then carried out at 0.275 M NaCl and 0.55 M
NaCl respectively for differential elution of clotting factors. Both of the latter elution steps included 0.05 M
sodium citrate, pH 6.5. Table 3 describes the presence of 3s various clotting factors in each purification step.
7~r~1en~o~r 1~
.
.
~ 3~3 Table 3 Quantitation of Clotting Factors in Purification Scheme Outlined in Example 2 ~ Total Uni~s Presence of Antigen Step F IX F X F. II P.C.
DEAE eluate 57420 145,290 Post Aerosil DEAE
eluate 57936 119,950 ~ +
Unbound column peak 5076 43,990 + +
0.275 M NaCl peak25376 ~0,512 - +
0.55 M NaCl peak 14076 1,173 lS While the separations obtained in this example are not optimum, this chromatography is illustrative of the fact that resolution of vitamin X-dependent factors i5 possible at very high flow rates. Of particular note is the obser-vation that Factor II (prothrombin) elutes in the unbound eluate and is not detectable in later elution steps. This was confirmed in elute and is not detectable in later elution steps. This was confirmed in similar chromato-graphic runs using specific F. II clotting assays. Protein C antigen is observed to co-chromatograph with F. X~ The recovery of F. X and F~ IX activities in the various elution steps is in good agreement with the total amounts of respective activities applied to the column.
EXAMPLE 3.
Stepwise Elution of Clotting Factors from Sulfated Trisacryl with Emphasis on the Removal of F. X from the F. IX
To a column of sulfated trisacryl with the dimensions described in Example 1 was applied 5 liters of a solution of DEAE eluate prepared as described in Example 2.
: CL-114 :' g3 N~ Aerosil adsorption of this solution was carried out.
Rather the sodium chl~ride concentration of the applied DEAE eluate was adjusted to 0.3 M pxior to application.
The column was also pre-equilibrated in 0.3 M NaCl, 0.05 M
5 sodium citrate, pH 6.5. After application of the sample, the column was washed with equi~ibration buffer to reduce the A280 of the column eluate to ~0.2. The Factor IX was then eluted in a single step with a buffer containing 0.55 M NaCl. The recoveries of Factors IX and X are given in 10 Table 4.
Table 4 Recoveries of Factors IX and X in the Sulfated Trisacryl Chromatography of Example 3 F. IX F. X
Step A280 units/ml total u. units/ml ~ ~ u.
DE~E eluate 5.41 4.9 24,580 14.5 72,500 (S liters)*
20 Unbound peak 1.22 0.59 10,500 4.1 72,980 (17.8 L) 0.55 M NaCl - 0.60 1.75 15,120 undete~ble eluted p~ak (8.64 L) This example demonstrates that it is possible to effec-tively remove F. X from the final F. IX preparation as eluted from the sulfated trisacryl. Since Factor X is, in our experience, the most troublesome and most likely contaminant ~rom among the other vitamin K-dependent 30 factors, it follows that the levels of other clotting factors such as F. II are also likely to be very low în the F. IX peak described here. Indeed, in other ~imilar chromatographies, prothrombin was fuund to be undetectable in F. IX peaks.
, . . . ~ } -
The elution profile of the column is shown in ~i~ure 1.
Fractions containing immunologically identifiable amounts 3s of Factors IX, X and Protein C are indicated in the Figure.
Protein C and Factor X were poorly resolved and eluted ~ Tî~e~or~
~ . ., .
early in the gradient at a sodium chloride concentration of approximately 0.15 - 0.3 M. Factor IX was observ~d to elute later in the gradient at approximately 0.4 M NaCl although there was some overlap with F. X.
The Factor IX-containing regions of the elution of similar column runs were pooled and dialyzed vs. 0.015 M sodium citrate containing 0.12 M NaCl. After concentration and sterile filtration, a partially purified F. IX preparation was obtained for animal studies with the following characteristics:
Factor IX activity 30.2 units/ml Protein concentration 4.41 mg/ml 15 F. IX spec. activity 6.85 units/mg NAPTT 1:10 163 sec 1:100 312 sec EXAMPLE 2.
Rapid Chromatography of DEAE Eluate on Sulfated Trisacryl with Quantitation of Factors II, VII, IX and X
A concentrate containing vitamin K-dependent clotting factors was obtained by contacting Effluent I plasma with 2s DE~E Sephadex and eluting the adsorbed gel as follows, After removal of the spent Effluent I, the DEAE gel was sequentially washed with ~1) 0.2 M sodium bicarbonate, ~2) 0.3 M sodium bicarbonate, and (3) 0.2 M sodium chloride containing 0.01 M sodium citrate, pH 6.5, The Factor IX
30 and other vitamin K-dependent fa~tors were then eluted from the DEAE gel with a buffex containing O.055 ~ NaCl and 0.01 M sodium citrate, p~l 6.5. The eluate was diafiltered against six volume exchanges of 0,05 M sodium citrate containing 0.1 M NaCl ! pH 6.5. 73 L of eluate were 3s ob ained and aliquots were frozen for ~ubsequent chromato-graphic studies. The content of clotting factors in the ~ T~A~th)~rl~
-~ CL-114 ,, :
~ .
., .
~ 3 g dialyzed eluate expressed as total units is given in Table .
Table 2 sContent of Vitamin K-dependent Clotting Factors in the Dialy~ed Eluate from DEAE Sephadex~
Contact of Eluate I
Units/ml To~al Units 10 Factor II (prothrombin) 12.0 876,000 Factor VII 2.5 182,130 Factor IX - 6.6 481,800 Factor X 12.8 919,800 Protein C positive for antigen lS Protein S- positive for antigen For the purpose of determining maximum flow characteristics of the sulfated trisacryl gel, a column of the following dimensions was constructed: height ~ 5 cml `, 20 diameter = 25 cm. B.7 liters of th DEAE elute described above was treated with Aerosil 380 at 0.25% w/v at 5 C for 60 minutes. The insoluble Aerosil was removed by filtra-tion and the clariied eluate applied to the sulfated trisacryl column at 24 liters/hour. ~Flow rates of up to 2S 60 liters per hour were obtained with this column configuration without visible deformation of gel or marked loss of column performance~. The elution profile of the column is shown in Figure 2. After application of the clarified DEAE elute, the column was washed with 0.1 M
NaCl, 0.05 M sodium citrate, pH 6~5. Separate step elutions were then carried out at 0.275 M NaCl and 0.55 M
NaCl respectively for differential elution of clotting factors. Both of the latter elution steps included 0.05 M
sodium citrate, pH 6.5. Table 3 describes the presence of 3s various clotting factors in each purification step.
7~r~1en~o~r 1~
.
.
~ 3~3 Table 3 Quantitation of Clotting Factors in Purification Scheme Outlined in Example 2 ~ Total Uni~s Presence of Antigen Step F IX F X F. II P.C.
DEAE eluate 57420 145,290 Post Aerosil DEAE
eluate 57936 119,950 ~ +
Unbound column peak 5076 43,990 + +
0.275 M NaCl peak25376 ~0,512 - +
0.55 M NaCl peak 14076 1,173 lS While the separations obtained in this example are not optimum, this chromatography is illustrative of the fact that resolution of vitamin X-dependent factors i5 possible at very high flow rates. Of particular note is the obser-vation that Factor II (prothrombin) elutes in the unbound eluate and is not detectable in later elution steps. This was confirmed in elute and is not detectable in later elution steps. This was confirmed in similar chromato-graphic runs using specific F. II clotting assays. Protein C antigen is observed to co-chromatograph with F. X~ The recovery of F. X and F~ IX activities in the various elution steps is in good agreement with the total amounts of respective activities applied to the column.
EXAMPLE 3.
Stepwise Elution of Clotting Factors from Sulfated Trisacryl with Emphasis on the Removal of F. X from the F. IX
To a column of sulfated trisacryl with the dimensions described in Example 1 was applied 5 liters of a solution of DEAE eluate prepared as described in Example 2.
: CL-114 :' g3 N~ Aerosil adsorption of this solution was carried out.
Rather the sodium chl~ride concentration of the applied DEAE eluate was adjusted to 0.3 M pxior to application.
The column was also pre-equilibrated in 0.3 M NaCl, 0.05 M
5 sodium citrate, pH 6.5. After application of the sample, the column was washed with equi~ibration buffer to reduce the A280 of the column eluate to ~0.2. The Factor IX was then eluted in a single step with a buffer containing 0.55 M NaCl. The recoveries of Factors IX and X are given in 10 Table 4.
Table 4 Recoveries of Factors IX and X in the Sulfated Trisacryl Chromatography of Example 3 F. IX F. X
Step A280 units/ml total u. units/ml ~ ~ u.
DE~E eluate 5.41 4.9 24,580 14.5 72,500 (S liters)*
20 Unbound peak 1.22 0.59 10,500 4.1 72,980 (17.8 L) 0.55 M NaCl - 0.60 1.75 15,120 undete~ble eluted p~ak (8.64 L) This example demonstrates that it is possible to effec-tively remove F. X from the final F. IX preparation as eluted from the sulfated trisacryl. Since Factor X is, in our experience, the most troublesome and most likely contaminant ~rom among the other vitamin K-dependent 30 factors, it follows that the levels of other clotting factors such as F. II are also likely to be very low în the F. IX peak described here. Indeed, in other ~imilar chromatographies, prothrombin was fuund to be undetectable in F. IX peaks.
, . . . ~ } -
Claims (7)
1. A sulfated, synthetic, noncarbohydrate affinity chromatography gel matrix adsorbing agent comprising a sulfatable polymer, said sulfatable polymer selected from the group consisting of a synthetic organic affinity chromatography gel matrix prepared by polymerization of at least one poly-merizable organic monomer, and polymeric silica particles, said sulfatable polymer having been treated by a process consisting essentially of treat-ing with a sulfating agent so as to provide a multi-plicity of sulfate groups bound directly to the polymer backbone.
2. An affinity chromatography gel matrix adsorbing agent according to claim 1, wherein said sulfatable polymer is said synthetic organic affinity chromatography gel matrix prepared by polymerization of at least one polymerizable organic monomer and is selected from the group consisting of sulfated poly-hydroxylated acrylates and methacrylates and sulfated polyvinylbenzene.
3. An affinity chromatography gel matrix adsorbing agent according to claim 2, wherein said sulfated polyhydroxylated acrylate is obtained by copolymerization of the monomer, N-acryloyl-2-amino-2-hydroxymethyl-1,3-propane diol.
4. In a method of isolating and purifying at least one of the group of blood coagulation factors and proteins selected from the group consisting of factors IX, X, II, VII, VIII, protein C, protein S, prothrombin and tissue plasminogen activator, from a source of said blood coagulation factors and proteins selected from blood, blood plasma, plasma concentrates and tissue culture fluids, obtained by means of bio-technology techniques, by the steps of (a) contacting the blood, blood plasma, plasma concentrates and tissue culture fluids with at least one affinity chromatography adsorbing agent, (b) separating the non-adsorbed solution from the non-adsorbing agent, and (c) eluting the adsorbed blood coagulation factors and proteins from the adsorbing agent using an eluant effective to elute the desired factor(s) and protein(s), the improvement comprising using as the adsorbing agent a sulfated, synthetic, non-carbohydrate affinity chromaography gel matrix adsorbing agent com-prising a sulfatable polymer, said sulfatable polymer selected from the group consisting of (i) a synthetic organic affinity chromatography gel matrix prepared by polymerization of at least one polymerizable organic monomer, and (ii) polymeric silica particles, said sulfatable polymer having been treated by a pro-cess consisting essentially of treating with a sul-fating agent so as to provide a multiplicity of sul-fate groups bound directly to the polymer backbone.
5. A method according to claim 4, wherein said sulfatable polymer is said synthetic organic affinity chromatography gel matrix prepared by polymerization or at least one polymerizable organic monomer and is selected from the group consisting of sulfated poly-hydroxylated acrylates and methacrylates and sulfated polyvinylbenzene.
6. A method according to claim 5, wherein the polymer backbone of said sulfated polyhydroxylated acrylate is obtained by copolymerization of the monomer, N-acryloyl-2-amino-2-hydroxymethyl-1,3-propane diol.
7. A method according to claim 4, including the step of treatment to render said blood coagulation factors and proteins non-infective by infectious viruses, including hepatitis virus, bacteria and retroviruses, including the AIDS-causing agent(s).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US754,569 | 1985-07-12 | ||
US06/754,569 US4721572A (en) | 1985-07-12 | 1985-07-12 | Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1265050A true CA1265050A (en) | 1990-01-30 |
Family
ID=25035374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000513596A Expired CA1265050A (en) | 1985-07-12 | 1986-07-11 | Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices |
Country Status (7)
Country | Link |
---|---|
US (1) | US4721572A (en) |
EP (1) | EP0208215B1 (en) |
JP (1) | JPH0724723B2 (en) |
AT (1) | ATE79052T1 (en) |
CA (1) | CA1265050A (en) |
DE (1) | DE3686295T2 (en) |
ES (1) | ES2002098A6 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2586359B1 (en) * | 1985-08-23 | 1989-09-08 | Commissariat Energie Atomique | SOLID SUPPORT BASED ON POLYVINYL ALCOHOL CAPABLE OF ADSORTING LIPOPROTEINS AND ITS USE FOR THE SEPARATION OF LOW DENSITY LIPOPROTEINS PRESENT IN A LIQUID SUCH AS BLOOD PLASMA |
AT399095B (en) * | 1986-03-27 | 1995-03-27 | Vukovich Thomas Dr | METHOD FOR SEPARATING PROTEINS BY MEANS OF GRADIENT ELUTION AND DEVICE FOR IMPLEMENTING THE METHOD |
JPS63209750A (en) * | 1987-02-25 | 1988-08-31 | Kanegafuchi Chem Ind Co Ltd | Adsorbent for purifying viii th blood coagulation factor and process for purifying said factor using the adsorbate |
EP0476721B1 (en) * | 1987-11-20 | 1995-03-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | A method for removing serum amyloid protein |
CA1330302C (en) * | 1988-01-18 | 1994-06-21 | Miroslav Rybak | Concentrates of coagulation factors ii, vii, ix and x, method of their preparation and use |
DE3826792C1 (en) * | 1988-08-06 | 1989-07-06 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
DK412389D0 (en) * | 1989-01-19 | 1989-01-19 | Novo Nordisk As | PROCEDURE FOR THE EXTRACTION OF PURIFIED EPI PROTEIN FROM A PROCESSING SOLUTION |
DE3914869C1 (en) * | 1989-05-05 | 1990-08-09 | Biotest Pharma Gmbh, 6072 Dreieich, De | |
US5110907A (en) * | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
AT402261B (en) * | 1991-01-25 | 1997-03-25 | Immuno Ag | COMPLEX CONTAINING THE coagulation factor IX |
AU663343B2 (en) * | 1991-10-04 | 1995-10-05 | Dade Behring Inc. | Preparation of prothrombin time reagents from recombinant human tissue factor and purified natural and synthetic phospholipids |
DE4325872C1 (en) * | 1993-08-02 | 1994-08-04 | Immuno Ag | Virus inactivated factor Xa preparation |
AU696924B2 (en) * | 1994-04-28 | 1998-09-24 | Dade Behring Inc. | Calibrator for prothrombin time (PT) assays |
US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
US5714583A (en) * | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
US5731186A (en) * | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
WO2006067230A1 (en) * | 2004-12-23 | 2006-06-29 | Novo Nordisk Health Care Ag | Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest |
NZ598381A (en) | 2009-09-10 | 2013-10-25 | Lonza Biologics Plc | Method and system for polypeptide purification |
KR20150023923A (en) | 2010-07-30 | 2015-03-05 | 이엠디 밀리포어 코포레이션 | Chromatogrphy media and method |
WO2012082723A2 (en) | 2010-12-15 | 2012-06-21 | Emd Millipore Corporation | Purification of immunogens using a non-polysaccharide matrix |
JP6652554B2 (en) | 2014-09-02 | 2020-02-26 | イー・エム・デイー・ミリポア・コーポレイシヨン | High surface area fiber media with nanofibrillated surface features |
JP6665184B2 (en) | 2014-12-08 | 2020-03-13 | イー・エム・デイー・ミリポア・コーポレイシヨン | Mixed bed ion exchange adsorbent |
GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
GB201506117D0 (en) * | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022758A (en) * | 1973-06-19 | 1977-05-10 | Ab Kabi | Isolation of coagulation factors I and VIII from biological material |
US3920625A (en) * | 1973-06-19 | 1975-11-18 | Kabi Ab | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
SE405549B (en) * | 1975-10-09 | 1978-12-18 | Pharmacia Fine Chemicals Ab | PROCEDURE FOR ISOLATING ALBUMIN FROM PLASMA PRODUCTS BY CHROMATOGRAPHIC FRACTIONING |
FR2459479B1 (en) * | 1979-06-21 | 1983-07-08 | Inst Nat Sante Rech Med | PROCESS FOR SEPARATING A PROTEIN SUBSTANCE FROM A SOLUTION CONTAINING IT BY AFFINITY FILTRATION AND APPLICATION OF SAID METHOD FOR ENZYMATIC ASSAYS |
US4296096A (en) * | 1979-07-05 | 1981-10-20 | Colgate-Palmolive Company | High viscosity dentifrice |
US4324689A (en) * | 1980-02-26 | 1982-04-13 | Shah Ramesh M | High carbon content chromatographic packing and method for making same |
US4415665A (en) * | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
US4447416A (en) * | 1982-04-28 | 1984-05-08 | American National Red Cross | Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy |
JPS5956161A (en) * | 1982-09-24 | 1984-03-31 | Hitachi Chem Co Ltd | Filler for column of liquid chromatography |
CA1221307A (en) * | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
DE3566409D1 (en) * | 1984-06-27 | 1988-12-29 | Organon Teknika Bv | Binder for low density lipoproteins |
US4606825A (en) * | 1985-04-22 | 1986-08-19 | J. T. Baker Chemical Company | Purification of immunoglobulin G |
-
1985
- 1985-07-12 US US06/754,569 patent/US4721572A/en not_active Expired - Lifetime
-
1986
- 1986-06-28 EP EP86108822A patent/EP0208215B1/en not_active Expired - Lifetime
- 1986-06-28 DE DE8686108822T patent/DE3686295T2/en not_active Expired - Lifetime
- 1986-06-28 AT AT86108822T patent/ATE79052T1/en not_active IP Right Cessation
- 1986-07-09 JP JP61159886A patent/JPH0724723B2/en not_active Expired - Lifetime
- 1986-07-11 CA CA000513596A patent/CA1265050A/en not_active Expired
- 1986-07-11 ES ES8600264A patent/ES2002098A6/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ES2002098A6 (en) | 1988-07-16 |
JPH0724723B2 (en) | 1995-03-22 |
US4721572A (en) | 1988-01-26 |
DE3686295T2 (en) | 1993-01-07 |
EP0208215B1 (en) | 1992-08-05 |
EP0208215A3 (en) | 1989-05-03 |
ATE79052T1 (en) | 1992-08-15 |
DE3686295D1 (en) | 1992-09-10 |
EP0208215A2 (en) | 1987-01-14 |
JPS6226227A (en) | 1987-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1265050A (en) | Purification of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices | |
US4138287A (en) | Purifying and isolating method for hepatitis virus to use in preparing vaccine | |
CA2024667C (en) | Process for preparing a concentrate of blood coagulation factor viii-von willebrand factor complex from total plasma | |
EP2102335B1 (en) | Purification of factor xi | |
Galaev et al. | Temperature-induced displacement of proteins from dye-affinity columns using an immobilized polymeric displacer | |
US5639857A (en) | Ultrapurification of factor IX and other vitamin k-dependent proteins | |
JPS5832591B2 (en) | Purification method of urokinase | |
JP2579217B2 (en) | Method for concentrating one or more of coagulation factors (II), (VII), (IX) and X | |
HU219828B (en) | Process for the isolation and purification of vitamin k dependent proteins | |
JP2593951B2 (en) | Method for isolating blood coagulation factor IX | |
WO1989005650A2 (en) | Chemical process | |
US5445958A (en) | Process for purifying blood clotting factors | |
JPS6034916A (en) | High purity purification of ix factor and other vitamin k dependent proteins | |
CA1283073C (en) | Adsorbent for purification of blood coagulation factor viii and process for purification of blood coagulation factor viii using the same | |
US6723539B1 (en) | Absorbent medium containing particles of chopped cellulose or agarose sponge material having functional groups | |
EP0813597B1 (en) | A process for the purification of vitamin k dependent coagulation factors by chromatography | |
CA1079272A (en) | Method for the purification of heparin | |
JP2882828B2 (en) | Method for purifying human urinary trypsin inhibitor | |
JPS6048930A (en) | Purification of antithrombin iii | |
AU627446C (en) | Chemical process | |
JPS5810522A (en) | Purification of antithrombin 3 by deactivated thrombin gel | |
JPH05262664A (en) | Adsorbent for blood coagulation factor viii | |
JPS641446B2 (en) | ||
JPS641447B2 (en) | ||
JPS63502718A (en) | Method for producing L-asparaginase from Erwinia carotvora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |